Related Experiment Videos
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia
Minoru Takemoto1, Takahiro Ishikawa, Shunichiro Onishi
1Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan. minoru.takemoto@faculty.chiba-u.jp
Abstract:
We examined the effects of atorvastatin on urinary podocyte excretion. Thirteen patients with type 2 diabetes receiving 2.5mg of rosuvastatin were recruited and the medication was switched to 10mg of atorvastatin for a 24-week period. With the switch to atorvastatin, the urinary excretion of podocytes was significantly reduced.
Related Concept Videos
Diabetic Retinopathy
Type II Diabetes II: Pathophysiology
Type I Diabetes II: Pathophysiology
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetic Nephropathy